CARDINAL HEALTH INC
CAHAPI behind this page
CAH FY 2025 request
Playground key active
/api/financials?ticker=CAH&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 222,578 | 226,827 | -1.9% |
Show Business Segments breakouts |
|||
| All Other Segments · at-Home Solutions | 3,480 | 2,869 | +21.3% |
| All Other Segments · Nuclear Precision Health Solutions | 1,578 | 1,369 | +15.3% |
| All Other Segments · Operating Segments | 5,382 | 4,512 | +19.3% |
| All Other Segments · OptiFreight Logistics | 324 | 274 | +18.2% |
| GMPD · Operating Segments | 12,636 | 12,381 | +2.1% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 204,644 | 210,019 | -2.6% |
Show Geography breakouts |
|||
| Non Us | 1,669 | 1,681 | -0.7% |
| US | 220,993 | 225,231 | -1.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -84 | -85 | +1.2% |
| Operating Segments | 222,662 | 226,912 | -1.9% |
| Cost of Revenue | 214,410 | 219,413 | -2.3% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,023 | 3,367 | +19.5% |
| GMPD · Operating Segments | 10,470 | 10,264 | +2.0% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 199,999 | 205,864 | -2.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 214,492 | 219,495 | -2.3% |
| Gross Profit | 8,168 | 7,414 | +10.2% |
| Selling, General & Administrative | 5,382 | 5,000 | +7.6% |
Show Product Lines breakouts |
|||
| Shipping And Handling | 909 | 866 | +5.0% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 843 | 722 | +16.8% |
| GMPD · Operating Segments | 2,031 | 2,025 | +0.3% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 2,387 | 2,140 | +11.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 5,261 | 4,887 | +7.7% |
| Restructuring Charges | 88 | 175 | -49.7% |
| Amortizationandotheracquisitionrelatedcosts | 464 | 284 | +63.4% |
| Acquisition Related Cash And Share Based Compensation Costs | 126 | — | — |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | 18 | 634 | -97.2% |
| Gain Loss Related To Litigation Settlement | -185 | 78 | -337.2% |
| Operating Income | 2,275 | 1,243 | +83.0% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 516 | 423 | +22.0% |
| GMPD · Operating Segments | 135 | 92 | +46.7% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 2,258 | 2,015 | +12.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -634 | -1,287 | +50.7% |
| Operating Segments | 2,909 | 2,530 | +15.0% |
| Other Non-Operating Income (Expense) | -41 | -9 | -355.6% |
| Interest Expense | 215 | 51 | +321.6% |
| Income Before Taxes | 2,101 | 1,201 | +74.9% |
| Income Tax Expense (Benefit) | 532 | 348 | +52.9% |
| Net Income | 1,569 | 853 | +83.9% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 8 | 1 | +700.0% |
| Net Income Loss Attributable To Noncontrolling Interest | -8 | -1 | -700.0% |
| Net Income | 1,561 | 852 | +83.2% |
| EPS (Basic) | 6.48 | 3.48 | +86.2% |
| EPS (Diluted) | 6.45 | 3.45 | +87.0% |
| Wtd Avg Shares (Basic) | 241 | 245 | -1.6% |
| Wtd Avg Shares (Diluted) | 242 | 247 | -2.0% |
| Total Costs & Expenses (FY) | — | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,866 | 4,089 | +19.0% |
| GMPD · Operating Segments | 12,501 | 12,289 | +1.7% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 202,386 | 208,004 | -2.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 219,753 | 224,382 | -2.1% |
| Comprehensive Income | 1,573 | 836 | +88.2% |
| Other Comprehensive Income | 12 | -16 | +175.0% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -3 | -1 | -200.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | 15 | -15 | +200.0% |
| Accumulated Other Comprehensive Income | 12 | -16 | +175.0% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,874 | 5,133 | -24.5% |
| Receivables Net Current | 13,242 | 12,084 | +9.6% |
| Inventory | 16,831 | 14,957 | +12.5% |
| Other Assets Current | 2,414 | 2,663 | -9.4% |
| Assets Of Disposal Group Including Discontinued Operation | 12 | 47 | -74.5% |
| Total Current Assets | 36,373 | 34,884 | +4.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,858 | 2,529 | +13.0% |
Show Geography breakouts |
|||
| Non Us | 436 | 423 | +3.1% |
| US | 2,422 | 2,106 | +15.0% |
| Other Non-Current Assets | 1,714 | 1,258 | +36.2% |
| Total Assets | 53,122 | 45,121 | +17.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,045 | 2,606 | +55.2% |
| GMPD · Operating Segments | 6,889 | 7,047 | -2.2% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 37,313 | 29,149 | +28.0% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 601 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 4,875 | 6,319 | -22.9% |
| Operating Lease Right-of-Use Assets | 758 | 475 | +59.6% |
| Goodwill | 9,691 | 4,725 | +105.1% |
Show Business Segments breakouts |
|||
| All Other Segments | 1,748 | 1,170 | +49.4% |
| Pharmaceutical and Specialty Solutions | 7,943 | 3,555 | +123.4% |
Show Business Acquisition breakouts |
|||
| ADS | 578 | — | — |
| GIA | 3,124 | — | — |
| ION | 910 | — | — |
| Specialty Networks | 784 | — | — |
| Urology America | 307 | — | — |
| Intangible Assets | 2,473 | 1,713 | +44.4% |
Show Business Acquisition breakouts |
|||
| ADS · Customer Related Intangible Assets | 472 | — | — |
| ADS · Trademarks, trade names, and patents | 28 | — | — |
| GIA · Noncompete Agreements | 23 | — | — |
| GIA · Trademarks, trade names, and patents | 200 | — | — |
| ION · Customer Related Intangible Assets | 226 | — | — |
| ION · Trademarks, trade names, and patents | 73 | — | — |
| Specialty Networks · Customer Related Intangible Assets | 480 | — | — |
| Specialty Networks · Developed Technology Rights | 20 | — | — |
| Specialty Networks · Noncompete Agreements | 5 | — | — |
| Specialty Networks · Trademarks, trade names, and patents | 15 | — | — |
| Urology America · Trademarks, trade names, and patents | 33 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Related Intangible Assets | 1,237 | 1,197 | +3.3% |
| Developed Technology Rights | 304 | 363 | -16.3% |
| Noncompete Agreements | 51 | — | — |
| Trademarks, trade names, and patents | 881 | 153 | +475.8% |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 12,177 | 6,450 | +88.8% |
| Current Liabilities | |||
| Accounts Payable | 34,713 | 31,759 | +9.3% |
| Long Term Debt And Capital Lease Obligations Current | 550 | 434 | +26.7% |
| Other Accrued Liabilities Current | 3,634 | 3,447 | +5.4% |
| Total Current Liabilities | 38,897 | 35,640 | +9.1% |
| Non-Current Liabilities | |||
| Deferred Tax And Other Liabilities Noncurrent | 8,882 | 8,035 | +10.5% |
| Operating Lease Liabilities | 654 | 400 | +63.5% |
| Total Liabilities (Q) | — | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 187 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 7,977 | 4,658 | +71.3% |
| Stockholders' Equity | |||
| Common Stock | 2,956 | 2,917 | +1.3% |
| Retained Earnings | 783 | -286 | +373.8% |
| Treasury Stock Value | -6,365 | -5,677 | -12.1% |
| Accumulated Other Comprehensive Income | -155 | -167 | +7.2% |
| Total Stockholders' Equity | -2,781 | -3,213 | +13.4% |
| Minority Interest | 147 | 1 | +14600.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,634 | -3,212 | +18.0% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -141 | -138 | -2.2% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | -14 | -29 | +51.7% |
| Accumulated Other Comprehensive Income | -155 | -167 | +7.2% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -155 | — | — |
| Common Stock | 2,956 | 2,917 | +1.3% |
| Noncontrolling Interest | 147 | 1 | +14600.0% |
| Retained Earnings | 783 | -286 | +373.8% |
| Total Liabilities & Equity | 53,122 | 45,121 | +17.7% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 790 | 710 | +11.3% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 88 | 79 | +11.4% |
| GMPD · Operating Segments | 212 | 205 | +3.4% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 185 | 184 | +0.5% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 305 | 242 | +26.0% |
| Gain Loss On Sale Of Other Investments | 3 | 2 | +50.0% |
| Stock-Based Compensation | 244 | 121 | +101.7% |
| Deferred Income Taxes | 243 | -104 | +333.7% |
| Provision For Doubtful Accounts | 53 | 36 | +47.2% |
| Increase Decrease In Receivables | -833 | -996 | +16.4% |
| Change in Inventory | -1,816 | 1,115 | -262.9% |
| Change in Accounts Payable | 2,732 | 1,824 | +49.8% |
| Increase Decrease In Other Operating Capital Net | -606 | -433 | -40.0% |
| Net Cash from Operations | 2,397 | 3,762 | -36.3% |
| Investing Activities | |||
| Capital Expenditures | -547 | -511 | -7.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | -5,250 | -1,190 | -341.2% |
| Proceeds From Hedge Investing Activities | 2 | 34 | -94.1% |
Show Date Initiated [Axis] breakouts |
|||
| January 2023 | 28 | — | — |
| June 2027 [Member] | 6 | — | — |
| Proceeds From Other Deposits | 200 | 350 | -42.9% |
| Increase Decrease In Other Investing Items Net | 2 | 18 | -88.9% |
| Net Cash from Investing | -5,593 | -1,849 | -202.5% |
| Financing Activities | |||
| Proceeds From Debt Net Of Issuance Costs | 3,669 | 1,139 | +222.1% |
| Payments To Minority Shareholders | 12 | — | — |
| Repayments Of Long Term Debt | -445 | -783 | +43.2% |
| Netproceedstaxwithholdingsfromsharebasedcompensation | -13 | 46 | -128.3% |
| Payments Of Dividends Common Stock | -494 | -499 | +1.0% |
| Share Repurchases | 765 | 750 | +2.0% |
| Net Cash from Financing | 1,940 | -847 | +329.0% |
| Supplemental | |||
| Interest Paid | 315 | 214 | +47.2% |
| Income Taxes Paid | 444 | 191 | +132.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -3 | -9 | +66.7% |
| Net Change in Cash | -1,259 | 1,057 | -219.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,874 | 5,133 | -24.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.